X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
FloraStilbene (mifepristone and pterostilbene) to stimulate the immune system in advanced breast cancer patients. Preclinical data demonstrated that FloraStilbene overcame immune suppression induced in the 4T1 mouse model of triple negative breast cancer.
Lead Product(s): Mifepristone,Pterostilbene
Therapeutic Area: Oncology Product Name: FloraStilbene
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
FloraStilbene (RU486 and pterostilbene) to stimulate the immune system in advanced breast cancer patients. Preclinical data demonstrated that FloraStilbene overcame immune suppression induced in the 4T1 mouse model of triple negative breast cancer.
Lead Product(s): Mifepristone,Pterostilbene
Therapeutic Area: Oncology Product Name: FloraStilbene
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2023
Details:
Under the collaboration, Cure Stat Rx will manufacture first in class breast cancer immunotherapy product FloraStilbene™ for a planned 12 patient Phase I/II trial aimed at assessing immunomodulatory activity of the drug candidate in advanced breast cancer patients.
Lead Product(s): Mifepristone,Pterostilbene
Therapeutic Area: Oncology Product Name: FloraStilbene
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cure Stat Rx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 15, 2023
Details:
JadiCells, as well as QuadraMune®, a commercially available nutraceutical developed by the Company have been shown to reduce lung scarring in other experiments.
Lead Product(s): Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area: Infections and Infectious Diseases Product Name: QuadraMune
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2021
Details:
Using a standard test for natural killer cell activity, the K562 lysis assay, 12 healthy volunteers taking one week of placebo had an average activity of 2.3 (±0.6), whereas those taking one week of QuadraMune™ had an average activity of 5.2 (±1.2), almost double.
Lead Product(s): Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area: Infections and Infectious Diseases Product Name: QuadraMune
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2020
Details:
QuadraMune™ is a nutraceutical developed by the Company which is currently in a clinical trial for prevention of COVID-19[1]. Minocycline is an antibiotic that is approved by the FDA.
Lead Product(s): Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area: Psychiatry/Psychology Product Name: QuadraMune
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2020
Details:
Pterostilbene is one of four ingredients which comprise QuadraMune™, a nutraceutical being developed by the Company which is currently in a clinical trial for prevention of COVID-19.
Lead Product(s): Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area: Neurology Product Name: QuadraMune
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2020
Details:
In a series of animal studies using the triple-negative breast cancer 4T1 mouse model, the Company showed that administration of QuadraMune™ reduced lung metastasis on its own and increased efficacy of a “cancer vaccine.
Lead Product(s): Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area: Oncology Product Name: QuadraMune
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2020
Details:
Administration of daily doses of QuadraMune™ in healthy volunteers results in statistically significant increases in immune response activity within 5 days.
Lead Product(s): Pterostilbene,Sulforaphane,Green Tea Extract
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
